JP Morgan Maintains Overweight on Merck & Co, Raises Price Target to $165

JP Morgan analyst Chris Schott has reaffirmed an Overweight rating on Merck & Co (NYSE: MRK) and increased the price target from $150 to $165. This adjustment reflects a positive outlook for the company's performance in the market.